Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2019 Filed Sep 17, 2019 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-028561 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,251 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $137.38 | $913,714.38 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $136.51 to 139.80. The price reported above reflects the weighted average sale price. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:16 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-027909 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,155 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:16 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $138.11 | $110,488.00 |
DisclosureSEC source: 0001127602-19-027909 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,102 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:16 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $138.11 | $110,488.00 |
DisclosureSEC source: 0001127602-19-027909 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,902 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:16 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-027909 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:21 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $138.11 | $186,448.50 |
DisclosureSEC source: 0001127602-19-027915 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,707 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $138.11 | $603,126.37 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 15:53 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $139.21 | $417,630.00 |
DisclosureSEC source: 0001127602-19-027676 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,145 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 17:37 UTC |
TAYLOR RONALD RDirector
|
SaleResMed Common Stock | 4,429 | $136.34 | $603,863.15 |
DisclosureSEC source: 0001127602-19-027155 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,855 F1 · price: This transaction was executed in multiple trades at prices ranging from $136.32 to $136.43. The price reported above reflects the weighted average sale price. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:20 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-026838 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,609 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:20 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 763 | $131.12 | $100,044.56 |
DisclosureSEC source: 0001127602-19-026838 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 149,050 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:20 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $131.12 | $433,613.84 |
DisclosureSEC source: 0001127602-19-026838 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:20 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-026838 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:22 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 7,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026663 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,410 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:16 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 5,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026659 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,145 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:19 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 10,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026661 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,058 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 4,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026656 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:08 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 10,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026650 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,902 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:05 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 17,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F3 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,902 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · shares: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $132.35 | $880,259.85 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $131.35 to 132.86. The price reported above reflects the weighted average sale price. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,101 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $128.56 | $561,421.52 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 16:57 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-025789 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,955 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 16:57 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $129.50 | $103,600.00 |
DisclosureSEC source: 0001127602-19-025789 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,623 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 16:57 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $129.50 | $103,600.00 |
DisclosureSEC source: 0001127602-19-025789 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,423 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 16:57 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-025789 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 22:45 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $129.14 | $387,420.00 |
DisclosureSEC source: 0001127602-19-025568 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,006 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Corrects misstatement of 492 certified RSUs that should have been included on the October 26, 2018 report. Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 01:55 UTC |
WAREHAM JOHN PDirector
|
GiftResMed Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025751 · form4.xml · nonDerivative · entry 1 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 F1 · kind: Gift of shares to the City of Hope and the Big Brothers Big Sisters 501(c)(3) organizations. Mr. Wareham has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:49 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 12,306 | $127.06 | $1,563,563.44 |
DisclosureSEC source: 0001127602-19-025470 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215 F1 · price: This transaction was executed in multiple trades at prices ranging from $126.62 to $127.60. The price reported above reflects the weighted average sale price. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 15:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-024715 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,916 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 15:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 804 | $124.50 | $100,098.00 |
DisclosureSEC source: 0001127602-19-024715 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 149,813 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 15:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $124.50 | $411,721.50 |
DisclosureSEC source: 0001127602-19-024715 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 15:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-024715 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,553 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $123.76 | $823,127.76 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.23 to $124.06. The price reported above reflects the weighted average sale price. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,468 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 236 | $124.40 | $29,357.93 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.22 to 124.58. The price reported above reflects the weighted average sale price. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,131 | $123.83 | $511,529.34 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,119 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.22 to $124.16. The price reported above reflects the weighted average sale price. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 23:32 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $123.17 | $369,510.00 |
DisclosureSEC source: 0001127602-19-023788 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,514 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:05 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-023656 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,038 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.